AR026400A1 - Quimioterapia de combinacion - Google Patents

Quimioterapia de combinacion

Info

Publication number
AR026400A1
AR026400A1 ARP000105899A ARP000105899A AR026400A1 AR 026400 A1 AR026400 A1 AR 026400A1 AR P000105899 A ARP000105899 A AR P000105899A AR P000105899 A ARP000105899 A AR P000105899A AR 026400 A1 AR026400 A1 AR 026400A1
Authority
AR
Argentina
Prior art keywords
agents
cancer
paclitaxel
combination
carboplatin
Prior art date
Application number
ARP000105899A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR026400A1 publication Critical patent/AR026400A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a un método para tratar tumores utilizando combinaciones de agentes oncolíticos conocidos. El uso de los agentes juntos proporcionainesperadamente una eficacia mayor que si se emplean agentes simples solamente. La quimioterapia del cáncer ha avanzado sustancialmente en anos recientes.Muchos tumores se han tratado efectivamente utiliando compuestos que son ya sea productos que ocurren naturalmente o agentes sintéticos. La quimioterapia delcáncer con frecuencia ocasiona el uso de una co mbinacion de agentes, generalmente como un medio para proporcionar efectos terapéuticos mayores y reducir losefectos individuales cuando se usan solos. Se relaciona con una combinacion sinergística de agentes antineoplásicos, y con un método para tra tar tumores quecomprenden la administracion de la combinacion. Más particularmente proporciona una composicion que comprende, como primer componente, la aceildinalina, comsegundo componente el paclitaxel o la carboplatina. También proporciona una com posicion que comprende los tres agentes juntos. Consisten esencialmente en losprincipios activos antes mencionados, o sales adecuadas de los mismos, junto con excipientes comunes, diluyentes y portadores. En otro método se emplea unacantidad antitumo r de acetildinalina y una cantidad efectiva de paclitaxel para tratar cánceres susceptibles, incluyendo NSCLC (cáncer de célula pulmonar nopequena), cáncer de mamas, cáncer de ovarios, cáncer de cabeza y cuello del utero, mielomas, cáncer de prostata y cáncer pancreático. La figura 1 muestra lasinergia de CI-994 y paclitaxel en las células del cáncer de colon el raton. La figura 2 muestra las actividades antitumor de CI-994, paclitaxel ycarboplatina, cada uno por separado, y el tratamiento de c ombinacion con los tres. Los datos que anteceden establecen una ineraccion favorable entre laacetildinalina en combinacion con paclitaxel o carboplatina, y en combinacion con ambas paclitaxel y carboplatina. De esta manera se proporciona un método pa ratratar neoplasmas susceptibles que comprende la administracion de los agentes anteriormente descriptos. La combinacion generalmente incluirá cada principio
ARP000105899A 1999-11-10 2000-11-09 Quimioterapia de combinacion AR026400A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16488999P 1999-11-10 1999-11-10
US22256100P 2000-08-03 2000-08-03

Publications (1)

Publication Number Publication Date
AR026400A1 true AR026400A1 (es) 2003-02-12

Family

ID=26860956

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105899A AR026400A1 (es) 1999-11-10 2000-11-09 Quimioterapia de combinacion

Country Status (17)

Country Link
EP (1) EP1229916A2 (es)
JP (1) JP2003513912A (es)
KR (1) KR20020060226A (es)
CN (1) CN1387438A (es)
AR (1) AR026400A1 (es)
AU (1) AU1583201A (es)
CA (1) CA2386876A1 (es)
GT (1) GT200000194A (es)
HU (1) HUP0203153A3 (es)
IL (1) IL149363A0 (es)
NZ (1) NZ518668A (es)
PA (1) PA8506201A1 (es)
PE (1) PE20011028A1 (es)
PL (1) PL355170A1 (es)
SV (1) SV2001000212A (es)
UY (1) UY26431A1 (es)
WO (1) WO2001034131A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
US9115090B2 (en) 2003-12-02 2015-08-25 The Ohio State University Research Foundation Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
MX2007000610A (es) * 2004-07-16 2007-03-07 Pfizer Prod Inc Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina.
PL2415382T3 (pl) 2010-08-06 2013-02-28 Electrolux Home Products Corp Nv Zmywarka nablatowa
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases

Also Published As

Publication number Publication date
CA2386876A1 (en) 2001-05-17
CN1387438A (zh) 2002-12-25
AU1583201A (en) 2001-06-06
WO2001034131A2 (en) 2001-05-17
GT200000194A (es) 2002-05-03
IL149363A0 (en) 2002-11-10
HUP0203153A3 (en) 2005-01-28
EP1229916A2 (en) 2002-08-14
WO2001034131A3 (en) 2002-05-10
PE20011028A1 (es) 2001-10-12
HUP0203153A2 (hu) 2003-01-28
SV2001000212A (es) 2001-10-25
JP2003513912A (ja) 2003-04-15
UY26431A1 (es) 2000-12-29
PA8506201A1 (es) 2002-12-11
KR20020060226A (ko) 2002-07-16
NZ518668A (en) 2004-04-30
PL355170A1 (en) 2004-04-05

Similar Documents

Publication Publication Date Title
AR026400A1 (es) Quimioterapia de combinacion
Messaoudi et al. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide
Treat et al. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study.
AR048502A1 (es) Sinergia terapeutica de compuestos anti-cancer
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
AR054094A1 (es) Tratamientos de cancer
BR0316004A (pt) Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina
BRPI0417260A (pt) derivados de azepinoindol como agentes farmacêuticos
ES2383771T3 (es) Homoharringtonina sola o combinada con otros agentes para su utilización en el tratamiento de la leucemia mielógena crónica resistente o intolerante a los inhibidores de la proteína cinasa diferentes al STI571
AR040792A1 (es) Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
Brunner The rationale of combined radiotherapy and chemotherapy–Joint action of castor and pollux
ATE344670T1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
CN101355969B (zh) 包含cyc-682和细胞毒性药物的抗增殖性组合
WO2018044369A3 (en) Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
Buocikova et al. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models
ES2164899T3 (es) Uso de alcaloides de la clase lamellarina en metodos de tratamiento.
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
CY1113509T1 (el) Ενισχυτης της επιδρασης κατα των ογκων, παραγοντας κατα των ογκων και μεθοδος θεραπειας για τον καρκινο
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
Samantas et al. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer: a Hellenic Cooperative Oncology Group Study
EA200801670A1 (ru) Комбинированная противораковая терапия с перфузией изолированного органа
Stewart et al. Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer
Emambux et al. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma
Pirker Two-versus three-drug combinations in the chemotherapy of advanced non-small-cell lung cancer

Legal Events

Date Code Title Description
FB Suspension of granting procedure